In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy.
With the results from the Delta and ACTG 175 clinical trials clearly showing an increased benefit of two drugs over monotherapy, combination nucleoside analog therapy looks set to play a major role in the battle against HIV. It is therefore essential that suitable combinations of drugs are used in clinical trials. We investigated the intracellular activation of zidovudine (ZDV), zalcitabine (ddC), and lamivudine (3TC) in MOLT-4 cells in two- and three-drug combinations at clinically achieved concentrations. The phosphorylation of ZDV and 3TC to their active triphosphate anabolites was not affected by the presence of the other drugs studied. However, the phosphorylation of ddC was significantly inhibited when incubated with 3TC, resulting in levels of ddC triphosphate (ddC-TP) less than 50% of control values. This can be explained by the requirement of both nucleoside analogs for the enzyme deoxycytidine kinase to carry out the initial step in their phosphorylation pathways, and by the comparatively low plasma concentrations of ddC achieved in vivo. These results suggest that regimens containing nucleoside analogs should be designed taking into account potential interactions affecting phosphorylation.
Veal
G J
GJ
Department of Pharmacology and Therapeutics, University of Liverpool, UK.
Barry
M G
MG
Khoo
S H
SH
Back
D J
DJ
D019380:Anti-HIV Agents / Q000378:metabolism / Q000494:pharmacology*; D001711:Biotransformation; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D006801:Humans; D019259:Lamivudine / Q000378:metabolism / Q000494:pharmacology*; D010766:Phosphorylation; D014407:Tumor Cells, Cultured; D016047:Zalcitabine / Q000378:metabolism / Q000494:pharmacology*; D015215:Zidovudine / Q000378:metabolism / Q000494:pharmacology*
D019380:Anti-HIV Agents; D019259:Lamivudine; D015215:Zidovudine; D016047:Zalcitabine